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analyses, which demonstrated defective intra-endothelial 
junctions with increased vesicles and decreased/disrupted 
glycocalyx. These results demonstrate that Ang-2 medi-
ates permeability via paracellular and transcellular routes. 
In patients suffering from stroke, a cerebrovascular disor-
der associated with BBB disruption, Ang-2 levels were 
upregulated. In mice, Ang-2 GOF resulted in increased 
infarct sizes and vessel permeability upon experimental 
stroke, implicating a role of Ang-2 in stroke pathophysiol-
ogy. Increased permeability and stroke size were rescued 
by activation of Tie2 signaling using a vascular endothelial 
protein tyrosine phosphatase inhibitor and were independ-
ent of VE-cadherin phosphorylation. We thus identified 
Ang-2 as an endothelial cell-derived regulator of BBB per-
meability. We postulate that novel therapeutics targeting 
Tie2 signaling could be of potential use for opening the 
BBB for increased CNS drug delivery or tighten it in neu-
rological disorders associated with cerebrovascular leakage 
and brain edema.
Keywords Blood–brain barrier (BBB) · Angiopoietin-2 · 
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Introduction
The blood–brain barrier (BBB) is a physiological barrier 
protecting the brain from circulating toxins and pathogens, 
yet providing essential substances such as iron and glu-
cose. The BBB is composed of microvascular endothelium 
supported by astroglia and pericytes together forming the 
neurovascular unit (NVU) [1, 17]. BBB maintains brain 
homeostasis by tightly controlling the access of plasma 
Abstract The homeostasis of the central nervous system 
is maintained by the blood–brain barrier (BBB). Angiopoi-
etins (Ang-1/Ang-2) act as antagonizing molecules to regu-
late angiogenesis, vascular stability, vascular permeability 
and lymphatic integrity. However, the precise role of angi-
opoietin/Tie2 signaling at the BBB remains unclear. We 
investigated the influence of Ang-2 on BBB permeability 
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strated an increase in permeability by Ang-2, both in vitro 
and in vivo. Expression analysis of brain endothelial cells 
from Ang-2 GOF mice showed a downregulation of tight/
adherens junction molecules and increased caveolin-1, a 
vesicular permeability-related molecule. Immunohisto-
chemistry revealed reduced pericyte coverage in Ang-2 
GOF mice that was supported by electron microscopy 
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components via intercellular tight junctions, efflux trans-
porters expressed on its luminal membrane and a negligible 
rate of vesicular transcytosis. The strict regulation of the 
BBB is essential in proper CNS functioning [25]. The BBB 
is deregulated in a large variety of neurological disorders 
that include brain ischemia, traumatic brain injury, high-
altitude cerebral edema, hepatic encephalopathy and many 
types of brain tumors. BBB deregulation can lead to brain 
edema and increased intracranial pressure, further deterio-
rating the clinical outcome. Thus, there is an urgent clinical 
need for novel strategies to prevent or treat BBB deregula-
tion [45, 56].
Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) 
are secreted growth factors that exert downstream signal-
ing through the Tie2 receptor tyrosine kinase [5, 24, 47]. 
Tie2 is predominantly expressed in endothelial cells and 
controls vessel remodeling and maturation [23, 47, 51]. 
Ang-1 activates the Tie2 receptor by phosphorylation, 
while Ang-2 is able to prevent receptor phosphorylation by 
competitive binding in a context-dependent manner, thus 
leading to inactivation of Tie2 and facilitating angiogenesis 
[5, 19, 28, 39, 47, 58]. Accordingly, Ang-2 is not expressed 
in the normal adult brain endothelium, but upregulated in 
brain tumors such as glioblastoma [32, 52, 57, 63]. Ang-
1, in contrast, has shown to be constitutively expressed in 
non-endothelial cells, such as pericytes [47]. These find-
ings suggest that Tie2 signaling in activated endothelium 
is mainly regulated via the expression of Ang-2 [47, 52]. 
We have previously demonstrated that Ang-2 overexpres-
sion in endothelial cells leads to an increase in myeloid cell 
infiltration via the β2-integrins [53]. This finding was sup-
ported by data obtained from human biopsies of inflamed 
tissues dominated by myeloid cell infiltration, where Ang-2 
was upregulated in endothelial cells [53]. Other studies 
indicated increased vascular permeability in peripheral 
endothelial cells upon Ang-2 expression that support the 
increased infiltration we observed [11, 64]. Furthermore, 
we found the highest levels of Ang-2 in myeloid-dominated 
inflamed brain tissues [53], prompting us to study the role 
of Ang-2 in cerebrovascular permeability that is tightly reg-
ulated by the BBB.
Ang-1 has been shown to result in vessel stabiliza-
tion and recruitment of mural cells, whereas Ang-2 leads 
to vessel destabilization and pericyte dropout [5, 24, 47]. 
Pericytes have been demonstrated to regulate neurovas-
cular permeability [4, 10, 18], suggesting a role for Angi-
opoietins at the BBB. Of note, Ang-1 has been reported 
to prevent vascular leakage [59, 60], while Ang-2 has 
been shown to increase vascular permeability in non-brain 
endothelial cells in vitro and in vivo [11, 64]. However, the 
precise role of Ang-2 at the BBB remains unclear.
To investigate the influence of Ang-2 at the BBB, we 
used primary mouse brain microvascular endothelial cells 
(MBMECs) for in vitro permeability measurements and 
performed in vivo studies with Ang-2 GOF mice which 
express Ang-2 in an inducible, endothelial-specific man-
ner (Ang-2 Tet-OS: Tie1 tTA) that we employed previ-
ously [46, 52, 53]. Expression analyses were carried out on 
freshly isolated brain microvessels (MBMVs), followed by 
localization and ultrastructural analyses in vivo (by means 
of immunofluorescence and electron microscopy). We 
have previously demonstrated increased Ang-2 levels in an 
experimental ischemia model in rodents [7, 8]. Here, we 
extend these observations by employing permeability stud-
ies using Ang-2 gain-of-function mice [46]. Permanent and 
transient mouse models of middle cerebral artery occlu-
sion were employed to this end. Therapeutic rescue was 
assessed at 24 h post-stroke, a time point characterized by 




The present study was performed in accordance with the 
German Protection of Animals Act and the guidelines for 
care and use of laboratory animals by the local commit-
tee (Regierungspraesidium Darmstadt, approval number 
FK/1044). Mouse lines comprising a Tie1 tTA driver and 
a TetOS human Ang-2 responder transgene were gener-
ated as described previously [46]. Mice received doxycy-
cline containing food pellets (100 mg/kg, ssniff Spezialdi-
aeten GmbH, Soest, Germany) during breeding. Transgene 
overexpression was induced from birth (P0) in newborn 
littermates by withdrawing doxycycline. Upon doxycy-
cline removal mice start displaying elevated serum levels 
of human Ang-2 [46]. Genotypes were determined by PCR 
analysis and expression levels of hAng-2 were monitored 
by ELISA. Unless otherwise noted, all the mice employed 
were adult (8–12 weeks, 25–30 g body weight) CD1 strain 
without gender discrimination. For transgenic mice, con-
trols were always littermates. Details about animal experi-
ments are presented in Suppl. Table 6.
Ethics statement for human specimens
All studies on human subjects were covered by an ethics 
statement. The ethics approval number for autopsy material 
is GS-249/11 and for resection material GS-04/09.
Statistical analysis
All statistical analyses were performed using Prism 5.0 
software (GraphPad). A value of p < 0.05 was considered 
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to be statistically significant. Data in graphs are represented 
as mean ± SEM with *p < 0.05; **p < 0.01; ***p < 0.001. 
The number of animals and experimental repeats are pre-
sented in Suppl. Table 6. This information is also indicated 
in the corresponding figure legends and the specific statisti-
cal test employed is indicated in the corresponding meth-
ods section.
ELISA studies
We monitored hAng-2 levels by ELISA in Ang-2 GOF 
mice as previously described [46]. In addition, hAng-2 
serum levels were determined in healthy human volunteers 
and stroke patients using the hAng-2 Quantikine ELISA 
kit according to the manufacturer’s instructions (R&D 
Systems). Detailed patient data are provided in the Suppl. 
Table 4 (healthy volunteers, n = 16; lacunar stroke patients, 
n = 4; territorial stroke patients, n = 15). Statistical analy-
sis was performed by one-way ANOVA followed by Dun-
nett’s post hoc test.
Permanent middle cerebral artery occlusion (pMCAO)
Experiments were performed as described previously [9]. 
In detail, animals were anesthetized intraperitoneally (i.p.) 
with a combination of midazolam/medetomidine/fentanyl 
(5/0.5/0.05 mg/kg body weight). Using an operating micro-
scope, the skin between the lateral part of the left orbit and 
the left external auditory meatus was incised. The top and 
back segments of the temporal muscle were transected, and 
the skull was exposed by retraction of the muscle. A small 
opening (1–2 mm in diameter) was made with a handheld 
drill in the frontal bone about 1 mm rostral to the fusion 
of the zygoma and squamosal bone, and 3.5 mm ventral to 
the dorsal surface of the brain. The MCA was exposed after 
the dura was opened and retracted. The MCA was exposed 
and occluded by ligation using 10-0 nylon thread (Ethicon) 
and transected distal to the point of ligation. The retracted 
soft tissues were replaced, the wounds were sutured and the 
mice were placed back into their cages. Anesthesia was ter-
minated by i.p. injection of atipamezole/naloxone/flumaze-
nil 2.5/1.2/0.5 mg/kg body weight).
Following pMCAO, WT and Ang-2 GOF mice 
(C57BL/6 background) were sacrificed at 24, 72 h and 
7 days. Brains were isolated, embedded in Tissue TEK® 
O.C.T. and stored at −80 °C until use. Brain sections on 
objective slides were dried for 15 min at 37 °C, followed 
by dehydration in 80 % ethanol for 2 min and drying for 
5 min. The samples were then washed 3× in ddH2O and 
incubated in Giemsa staining solution (Merck) for 1 h at 
RT. The sections were immersed in glacial acetic acid for 
a few minutes and thereupon incubated in 96 and 100 % 
ethanol and xylene. Sections were mounted with Entellan 
(Merck). Images of infarct brain sections were taken and 
analyzed with a Stereo Investigator (MicroBrightField, 
Inc.). The infarct areas were measured for serial sections 
(spaced 100–200 µm) and these were combined to obtain 
the volume of the infarct size in mm3 taking into account 
the section thickness for volume calculation. The statisti-
cal analysis of stroke sizes was performed by two-tailed 
unpaired t test. Details about animal numbers are included 
in Suppl. Table 6.
Transient MCAO (tMCAO)
The operator was blinded to the genotype and treatment of 
mice. AKB-9785 was pre-administered at 14 and 2 h prior 
to surgery and 10 h post-surgery following tMCAO. CD1 
male mice were injected subcutaneously with AKB9785 
(30 mg/kg) or vehicle (dH2O) as a control. MCAO surger-
ies were performed as described previously [44]. Briefly, 
mice were anesthetized with 1.5 % isofluorane followed 
by right MCA occlusion using standardized monofilament 
(0.23 mm tip diameter, Doccol). 30 min after the occlu-
sion, the filament was removed and 24 or 72 h post-occlu-
sion mice were subjected to neurological deficit scoring 
according to 14-point modified neurological severity scores 
(mNSS) [14]. Mice were then killed and the brain was iso-
lated. The cerebellum and olfactory lobes were removed 
and subsequently the brain was cut into 2 mm-thick slices 
on a brain matrix. For each animal, three brain slices were 
transferred to 2,3,5-triphenyltetrazolium chloride (TTC, 
2 %). One additional slice was either utilized for native 
embedding into O.C.T. compound or stored in RIPA buffer 
plus proteinase/phosphatase inhibitors for Western blot 
analysis. The stroke sizes were determined and analyzed by 
two-tailed unpaired t test. Stroke incidence was in the range 
of 80–90 % and animals were only excluded when there 
was no stroke based on TTC staining. More than 80 % of 
animals survived MCAO surgery. The details are included 
in Suppl. Table 6.
In vivo tracer studies
Tracer experiments were performed in healthy WT or GOF 
mice and not in stroke-induced animals unless otherwise 
specified. A mixture (1:2) of Texas Red (TXR) or tetra-
methylrhodamine (TMR) 3 kD dextran (1 mM, Invitrogen) 
and Lucifer Yellow (LY; 10 mM, Sigma) was injected into 
the tail vein of mice (100 µl/mouse) and allowed to circu-
late for 4 min. This step was followed by anesthesia (as 
described before) and transcardial perfusion for 1 min with 
PBS. Brain and kidneys were isolated followed by homog-
enizing hemi-brain or a single kidney in PBS at 4 °C, and 
the remaining kidney and hemi-brain were frozen down in 
Tissue TEK® O.C.T. Compound (Sakura) on dry ice for 
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immunohistochemical analysis. After spinning down the 
samples at 10,000×g for 15 min at 4 °C, the supernatant 
was measured to obtain raw fluorescence units (RFU) in 
a fluorescence plate reader (Tecan) at excitation/emission 
wavelength of 425/525 nm for LY and 595/625 nm for 
TXR-3 kD dextran or 550 nm/580 nm for TMR 3 kD dex-
tran and normalized to the serum RFUs from blood with-
drawn immediately before perfusion. Kidneys were used as 
a positive control for tracer injections. In experiments using 
larger molecular weight tracers, 2 % Evans blue dye (70 
kD, albumin-bound form) was injected intravenously into 
the tail vein of mice and circulated for 2 h. After transcar-
dial perfusion with PBS, isolated brains were minced with 
a scalpel and transferred into a tube containing formamide. 
Samples were incubated at 67 °C for 24 h followed by cen-
trifugation at 10,000×g for 1 h at 4 °C. The absorbance of 
the supernatants was measured at 620 nm in a plate reader 
(Tecan). Statistical analysis of in vivo tracer experiments 
was performed by two-tailed unpaired t test.
Isolation of mouse brain microvessels (MBMVs)
Brains were isolated and rolled on a Whatman filter mem-
brane (Schleicher & Schuell) to peel off meninges. They 
were subsequently pooled, homogenized in MVB buffer 
[26] using a dounce homogenizer (Wheaton, 0.025 mm 
clearance) and centrifuged at 400×g for 10 min at 4 °C. 
The pellet was resuspended in 25 % BSA and centrifuged 
at 1500×g for 30 min to remove myelin fat that was aspi-
rated carefully from the top layer. The microvessel pellet 
containing red cells and nuclei was resuspended in MVB 
buffer and filtered through a 40 µm nylon mesh (BD). For 
protein analysis, microvessels were resuspended in HES 
buffer [21] with protease and phosphatase inhibitor cock-
tails (Roche) and stored at −80 °C. For mRNA expression 
analysis, the final microvessel sample was lysed in RLT-
plus buffer (Qiagen) and stored at −80 °C until use.
Isolation of mouse brain microvascular endothelial cells 
(MBMECs)
A modified protocol was utilized to isolate endothelial 
cells for in vitro cell culture experiments [37, 43]. Briefly, 
meninges-free brains were pooled and homogenized as 
described above followed by digesting the pellet with 
0.75 % collagenase II (Worthington) in buffer A (1:1:1 vol-
ume ratio) for 1 h with shaking at 37 °C. For the removal 
of myelin, samples were resuspended in 25 % BSA and 
centrifuged at 1500×g for 30 min at 4 °C followed by 
enzymatic digestion of the pellet with Collagenase/Dispase 
(Roche) and DNase I (Worthington) in buffer A for 12 min 
at 37 °C. After centrifugation, MBMECs were resus-
pended in MCDB-131 complete medium [15] and seeded 
on six-well plates pre-coated with type 1 collagen (150 µg/
cm2, Corning). After 4 h, the medium was changed to puro-
mycin (5 µg/ml) containing medium, which selects for 
ECs as they possess p-glycoprotein (P-gp) that effluxes out 
puromycin, a P-gp substrate [22, 37]. Contaminating cells 
do not possess P-gp and hence do not survive the treatment. 
The medium was changed back to puromycin-free medium 
after 3 days.
Culture of bEnd5 cells
To reduce the number of animals for MBMECs, immor-
talized brain endothelial cells (bEnd5) were obtained and 
cultured as described previously in MCDB-131 complete 
medium [15]. Dishes were gelatin coated (0.1 %, 30 min), 
followed by seeding the cells at 50,000 cells/cm2. For West-
ern blotting experiments, cells were cultured for 5–6 days 
to obtain a confluent monolayer followed by treatments in 
serum-free medium.
Culture and treatment of murine astrocytes and human 
pericytes
Astrocytes were isolated and cultured from postnatal mouse 
brains (0–4 days) as described previously [61]. They were 
then seeded onto 24-well plates pre-coated with 0.001 % 
poly-l-lysine for 30 min. Primary human brain vascular 
pericytes (ScienCell) were also seeded in a similar way. 
Upon confluency, the cells were treated with 0.1 % BSA/
PBS for 16 h which served as control, or with 500 ng/ml 
recombinant human Ang-2 for 16 h plus/minus 1 µM AKB-
9785 for 10 min followed by washing with PBS. Cells were 
lysed for 15 min on ice in RIPA buffer (Sigma) containing 
one tablet each of protease and phosphatase inhibitor cock-
tail (Roche). Following this, the samples were transferred 
into Eppendorf tubes and centrifuged at 16,000×g at 4 °C 
for 10 min. The supernatants were transferred into new 
Eppendorf tubes and stored at −80 °C until further use.
Transendothelial electrical resistance (TEER)/
capacitance (Ccl) measurements
MBMECs (100,000 cells/cm2, 4–6 mice/prep) isolated 
from CD1 wild-type mice were seeded onto 1 µm-pore 
24-well PET transwell inserts (Greiner Bio-One) pre-
coated with fibronectin (5 µg/cm2, Sigma-Aldrich). The 
inserts were transferred to a cellZscope® device (Nano-
Analytics) placed in a humidified incubator (37 °C, 5 % 
CO2) and TEER and Ccl values were obtained from con-
tinuous impedance measurements as described previously 
[15]. Treatment with hAng-2 (500 ng/ml) with or without 
AKB-9785 (1 µM) was started upon reaching a plateau 
in TEER/Ccl levels and continued up to 48 h. The TEER/
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Ccl measurements were statistically analyzed by two-way 
ANOVA with matching to account for inter-prep variations.
In vitro permeability assay
MBMECs were isolated from C57BL/6 mice pooling four 
to six animals in each preparation and cultured as described 
above on transwell inserts. Confluent cells were treated 
with recombinant hAng-2 (500 ng/ml) for 24 h. This was 
followed by performing the permeability assay for 0.45 kD 
LY (Sigma), TXR-3 kD dextran (Invitrogen), TMR-20 
kD dextran (Sigma) and FITC-70 kD dextran (Sigma) as 
described previously [15]. Briefly, the tracer mix was added 
to the apical chamber and media aliquots were collected 
from the top and bottom chamber at 1 h time point. The 
samples were read in a fluorescence plate reader (Tecan) 
at the corresponding tracer excitation/emission and perme-
ability obtained as bottom chamber fluorescence normal-
ized to the apical chamber fluorescence with the ratio for 
the control condition set to 100 %. For filipin experiments, 
cells were treated with hAng-2 (500 ng/ml, 1 h) alone or 
with AKB-9785 (1 µM) followed by filipin treatment 
(10 nM, 30 min). Permeability assay was then performed as 
above and top/bottom aliquots collected after 1 h and read 
in a plate reader. The in vitro permeability assays were sta-
tistically analyzed by one-way ANOVA with matching to 
account for inter-prep variations with Tukey post hoc test 
for multiple comparisons.
Immunohistochemical staining and quantification 
of murine cryosections
Brains were isolated and frozen in native state in Tissue 
TEK® O.C.T. Compound (Sakura) on dry ice and stored 
at −80 °C. For all stainings, unless specified otherwise, 
frontal coronal sections (10 µm, at the starting point of 
ventricles) were fixed in 95 % ethanol for 5 min at 4 °C 
and by acetone fixation for 1 min at room temperature (RT) 
followed by incubation with primary antibodies (Table 1) 
for 1.5 h at RT. Samples were post-fixed in 4 % PFA and 
mounted with AquaPoly Mount (Polysciences). Images (5/
section) were acquired with a C1si confocal microscope 
(Nikon) with 20× and 60× objectives. The number of 
desmin-positive cells were counted using NIS Elements 
AR Imaging Software 4.10 (Nikon) and expressed in per-
cent normalized to number of CD31-positive cells. A two-
tailed unpaired t test was performed for statistical signifi-
cance. The astrocytic endfeet coverage was analyzed by the 
number of endfeet processes normalized to the number of 
CD31-positive vessels at 20× magnification. The length of 
the astrocytic endfeet processes was obtained by analyzing 
three images per animal at 60× magnification. A two-tailed 
unpaired t test was performed for statistical significance.
The same procedure was followed for IgG staining from 
either PFA-fixed (tMCAO) or native (pMCAO) samples. 
Three equal area regions of interest (ROI) around the ves-
sels were chosen for the analysis of mean intensity from 
a single image per animal by NIS Elements AR Imaging 
Software 4.10 (Nikon). A two-tailed unpaired t test was 
employed for statistical analysis.
For pTie2/Tie2 staining, the frontal coronal sections 
were fixed immediately post-sectioning in ice-cold metha-
nol/acetone for 10 min, air-dried and stored at −80 °C until 
use. Sections were washed once in PBS and blocked for 
60 min in 20 % NDS/1 % BSA in PBS. The samples were 
incubated in primary and secondary antibodies (diluted in 
1 % BSA/PBS) at RT for 1.5 h each step. Image acquisition 
was performed as mentioned above using 40× objectives 
(n = 5 per group were analyzed).
Immunohistochemical staining and quantitation 
of murine vibratome sections
For quantitative analysis of pericyte coverage in brain 
vasculature, mice (n = 3 for each genotype) were anes-
thetized and transcardially perfused with PBS for 1 min 
as described earlier followed by 4 min with 4 % PFA. The 
brains were dissected and post-fixed overnight in 4 % par-
aformaldehyde. Serial 50 µm coronal sections were cut on 
a Leica Vibratome (VT 1000S). At least four sections at 
intervals of 500 µm were analyzed on a Nikon C1 Spec-
tral Imaging Confocal Laser Scanning Microscope Sys-
tem, using NIS Elements Microscope Imaging Software 
(Nikon Instruments, Inc., Düsseldorf, Germany). Video 
clips were prepared using Imaris 7.6.5, Bitplane Scientific 
Software.
The following primary antibodies were used: mouse 
monoclonal anti-desmin (#M0760, Dako, 1:100) and rab-
bit polyclonal anti-collagen IV (#2150-1470, Abd serotec, 
1:250). Antigen retrieval was performed prior to the staining 
Table 1  Antibodies for immunohistochemical analysis









Abd Serotec 2150-1470 1:250
Aquaporin-4 Astrocytes Millipore AB2218 1:200
Human Ang-2 Ang-2 R&D MAB 0983 1:100




Tie2 Tie2 R&D AF762 1:50
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procedure by heating the sections in a 10 mM citric acid 
buffer, pH 6.0. Samples were incubated with primary anti-
bodies at 4 °C over night followed by incubating with the 
following secondary antibodies: goat anti-mouse IgG Alexa 
Fluor 488 and goat anti-rabbit IgG Alexa Fluor 647.
Immunohistochemical staining and quantification 
of human stroke samples
Human brain sections derived from 28 autopsy specimens 
(Suppl. Table 5) pre-fixed in 10 % formaldehyde and paraf-
fin embedded were first de-paraffinized followed by anti-
gen retrieval. Hematoxylin/Eosin staining was performed 
according to standard protocols, followed by histopatholog-
ical grading (stroke grades I–III) according to Mena et al. 
[40]. A Ventana Benchmark automated system was used for 
hAng-2 staining (Table 2) using standard protocol utilizing 
cell conditioning 1 (pre-diluted, Ventana Medical Systems) 
solution for antigen retrieval. Primary antibody signal was 
detected with IHC Ultra Map AT kit (Ventana Medical Sys-
tems). From the acquired images, Ang-2-positive vessels 
were counted and given a score from 0 to 3 (with 0 being 
no Ang-2 signal and 3 being the maximum; n = 13 cases, 
whiskers plot (2.5–97.5 percentile), Kruskal–Wallis test 
with Dunn’s multiple comparison test).
Western blotting
Samples were solubilized in urea/SDS buffer (2.3 M urea, 
1.5 % SDS, 50 mM Tris, 25 mM TCEP and 0.01 % BPB) 
for 1.5 h at 30 °C with shaking [21]. The solubilized sam-
ples were subjected to electrophoresis on Tris–HCl bis-
acrylamide gels (8–15 %) and subsequently transferred 
to nitrocellulose membranes at 4 °C ON. The membranes 
were blocked for 1 h at RT in 1x Roti®-block (Roth) and 
incubated with primary antibodies (Table 2) overnight at 
4 °C, washed with PBS-T (0.5 % Tween-20) and incubated 
with horseradish peroxidase-conjugated or fluorescent sec-
ondary antibodies (LI-COR) for 1 h at RT. The membranes 
were imaged in Odyssey (LI-COR) imaging device and not 
by classical chemiluminescence using films and therefore 
produced very little background. An artificial black and 
white color has been included for the color of the blots 
and hence appears overly processed. All the quantification 
was however done on raw images using Image Studio 2.1 
software (LI-COR) as described previously [21, 22]. The 
Western blots of MBMV were statistically analyzed by 
two-tailed unpaired t test (7 mice/prep). MBMECs from 
C57BL/6 mice (3–4 mice/prep) and bEnd5 cells (between 
passages 25–30) were pre-treated in serum-free condition 
for 16 h with recombinant hAng-2 (500 ng/ml) followed by 
AKB-9785 treatment (bEND5: 1, 10 or 50 µM; MBMECs: 
50 µM) for 10 min. Data were analyzed by two-tailed 
unpaired t test for statistical significance.
qPCR analysis
The SYBR® Green system (Thermo Scientific) was used 
for qPCR analysis. The reaction of qPCR was performed 
in ABgene PCR plates (Thermo Scientific), sealed with a 
Clear Seal Diamond Heat Sealing Film (Thermo Scien-
tific) and run in a CFX96™ Real-Time System (Bio-Rad) 
as described previously [15]. Using the reference gene, 
the relative expression of cDNA was calculated with CFX 
manager 3.1 software (Bio-Rad). The statistical analysis 
was performed by two-tailed unpaired t test. The primers 
used are listed in Table 3.
Electron microscopy
CD1 mice (n = 3 for each genotype) were anesthetized and 
transcardially perfused with PBS for 1 min as described ear-
lier followed by 4 min with 4 % PFA/2 % glutaraldehyde 
in PBS. The isolated brains were post-fixed with the same 
fixative ON at 4 °C. The tissue (cut into small pieces) was 
additionally post-fixed with 1 % OsO4 for 2.5 h at RT and 
stained with 2 % uranyl acetate solution at 4 °C ON prior to 
Table 2  Antibodies for Western blot analysis
Antibody Company Catalog # Dilution
α-Tubulin Sigma-Aldrich T6199 1:500
Claudin-5 Invitrogen 35-2500 1:500
β-Catenin BD 610154 1:500
Caveolin-1 Santa Cruz SC-894 1:500
Glut-1 See Ref. [21] Not applicable 1:1000
β-Actin Santa Cruz sc-69879 1:1000
pTie2 R&D AF2720 1:400
Tie2 R&D AF762 1:500
pVE-cadherin Abcam ab27776 1:1000
VE-cadherin Santa Cruz sc-6458 1:500
pAkt Cell Signaling 4060S 1:1000
Akt Cell Signaling 9272S 1:1000
Table 3  Primers used for q-RT-PCR analysis
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dehydration in graded acetone and embedded in Durcupan. 
The polymerization was performed at 60 °C for 72 h.
For the quantification of vesicles, 20 cortical vessels of 
comparable size were analyzed for each animal (n = 3 per 
genotype). For the presence of gaps within EC junctions, 
and for pericyte degeneration and pericyte coverage, 100 
cortical vessels were analyzed from each brain (n = 5 for 
each genotype). Data were analyzed by one-sample t test 
as for gaps in EC junctions and Student’s unpaired t test for 
the rest.
To stain for the glycocalyx, mice (n = 3 each geno-
type) were anesthetized as described above and perfused 
with 2 % glutaraldehyde, 2 % saccharose, 0.1 M sodium 
cacodylate buffer and 2 % lanthanum nitrate (pH 7.4). 
Brains were isolated and fixed for 2 h in the perfusion solu-
tion and subjected to 2 % H2O2, 2 % saccharose, 0.1 M 
sodium cacodylate buffer and 2 % lanthanum nitrate for 
12 h at 4 °C followed by rinsing with 0.03 M NaOH and 
2 % saccharose. The contrast was increased by using a 2 % 
OsO4 and 2 % lanthanum nitrate followed by dehydration 
in graded ethanol and propylene oxide and embedding in 
araldite. The polymerization was performed at 60 °C for 
12 h. For standard processing, ultrathin sections were con-
trast enhanced with uranyl-acetate and lead citrate. The 
analysis of glycocalyx was performed without any con-
trast enhancement to rule out an unspecific precipitation of 
the staining solutions. Sections were analyzed using Tec-
nai Spirit BioTWIN FEI electron microscope at 120 kV. 
Images were taken with an Eagle 4K CCD bottom-mount 
camera.
HRP detection by electron microscopy
HRP tracer (type II, Sigma) was injected via tail vein into 
WT or Ang-2 GOF (10 mg/mouse) and allowed to circu-
late for 30 min before killing the mice. The brains were dis-
sected and transferred into 5 % glutaraldehyde/4 % PFA/PB 
for 60 min at RT. After post-fixation in 4 % PFA/PB at 4 °C 
for 5 h, the brains were washed in PB at 4 °C ON. Serial 
coronal sections (50 µm) were cut on a Vibratome (Leica, 
VT1000S) and stained with 5 mg DAB/10 ml 0.05 M Tris–
HCl, pH 7.6, containing 0.01 % H2O2 for 45 min at RT 
(DAB (3,3′-diaminobenzidine tetrahydrochloride, Sigma). 
Small regions of cortex were cut out and processed for 
electron microscopy as described previously. Shortly, sec-
tions were washed twice with PBS for 30 min. The tissue 
was then post-fixed with 1 % OsO4/1.5 % K3Fe(CN)6 for 
2 h at RT, washed with dH2O followed by dehydration in 
graded acetone solutions and embedded in Durcupan. The 
polymerization was performed at 60 °C for 48 h.
Mice without HRP injection that were processed in the 
same way served as controls. For quantitation, vesicles 
and junctions of 30 vessels per brain were analyzed for 
the presence of HRP (n = 3 for each genotype). Data were 
analyzed by one-sample t test for HRP+ junctions and Stu-
dent’s t test for the amount of HRP+ vesicles normalized to 
the total number of vesicles.
Flow cytometry
Normal brains of adult Ang-2 GOF mice and wild-type 
littermates were dissected and immediately transferred in 
ice-cold HBSS. Briefly, following gentle mincing, the tis-
sue was incubated in an HBSS solution containing Col-
lagenase P (0.2 mg/ml), Dispase II (0.8 mg/ml), DNase 
I (0.01 mg/ml), Collagenase A (0.3 mg/ml) for 60 min at 
37 °C under gentle rocking as previously described [52]. 
Following myelin removal, the cells were preincubated 
with rat anti-mouse FcγIII/II receptor (CD16/CD32) block-
ing antibodies (≤1 μg/million cells/100 μl; BD) for 5 min 
at 4 °C, and stained with the fluorochrome-conjugated anti-
bodies (0.25–1 µg): CD45 PercP Cy5.5 (clone 30-F11, BD 
Biosciences), Gr-1 APC-Cy7 (clone RB6-8C5, BD Bio-
sciences), CD11b APC (clone M1/70, BD), F4/80 FITC 
(clone BM8, eBioscence). Following two washing steps, 
DAPI (4′,6-diamidino-2-phenylindole; Invitrogen) was 
added for live gating and cells were acquired on a FAC-
SCanto™ II flow cytometer (BD) using Diva Software 
(BD) and further analyzed using FlowJo analytical soft-
ware (FlowJo Version 10.0.8, LLC). Background fluores-
cence levels were determined by Fluorescence Minus One 
(FMO).
Results
The effect of Ang-2 on BBB permeability was first 
assessed by transendothelial electrical resistance (TEER) 
and capacitance (Ccl) measurements on the primary 
mouse brain endothelial cells (MBMECs) (Fig. 1a). The 
TEER of MBMECs derived from Ang-2 GOF mice was 
lower compared to WT (Fig. 1b), and Ccl was higher 
(Suppl. Fig. 1a) indicating a barrier-opening effect of 
Ang-2. Similar results were obtained when WT-MBMECs 
were treated with recombinant Ang-2 (hAng-2, Fig. 1c). 
The permeability to fluorescent dextrans (3, 20, and 
70 kD) and Lucifer Yellow (LY 0.45 kD) [15] was also 
increased in TEER measurement by hAng-2 (Fig. 1d), 
suggesting a direct effect of Ang-2 on brain EC perme-
ability. In vivo, the permeability to LY and 3 kD dex-
trans (Texas Red and TMR) was significantly increased 
in Ang-2 GOF (Fig. 2a, c), with no difference for Evans 
blue dye (~70 kD) potentially owing to a tight barrier 
in vivo (Fig. 2b). The 0.45 kD LY and 3 kD dextran trac-
ers were circulated for 4 min due to their rapid clearance 
from blood vessels at longer time points (Suppl. Fig. 1b). 
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Kidneys served as a control for tracer permeability that 
was not altered between GOF and WT (Suppl. Fig. 1c). 
These results therefore demonstrate Ang-2-mediated brain 
endothelial permeability for low molecular weight solutes 
in vivo. 
We next elaborated the molecular components of Ang-
2-mediated permeability by immunohistochemistry (IHC), 
electron microscopy (EM) and Western blots. Quantitative 
RT-PCR analysis confirmed an overexpression of hAng-2 
in the isolated brain microvessels of Ang-2 GOF mice, 
whereas Tie2 expression levels were not altered (Suppl. 
Fig. 1d). Furthermore, we did not observe an increase in 
Ang-1 levels (Suppl. Fig. 1e, f) in these mice, suggesting an 
absence of its compensatory effects. IHC from cryosections 
(10 µm) and from vibratome sections (50 µm) revealed a 
decrease in pericytes in GOF (Fig. 3a, b; Suppl. video) as 
previously observed in the periphery [53]. In Fig. 3a, we 
set the WT pericyte coverage to 100 %; however, the abso-
lute pericyte coverage of the vessels is only about 20–25 % 
as obtained from vibratome data analysis which is reduced 
to approximately 12–15 % in the GOF mice. Also by EM 
analysis, we observed decreased pericyte coverage with 
increased numbers of degenerating pericytes in Ang-2 GOF 
mice (Fig. 4a–c; Suppl. Table 1). EM analysis also showed 
increased caveolae-like vesicles (Fig. 4a, e) that are partly 
responsible for peripheral endothelial permeability. The 
analysis also revealed decreased complexity of the inter-
endothelial junctions in GOF, with frequent gaps (Fig. 4a, 
d; Suppl. Fig. 2a; Suppl. Table 2), indicating increased 
paracellular permeability. Furthermore, the glycocalyx 
thickness was considerably disrupted/decreased (~300–
~100 nm, Fig. 5a; Suppl. Fig. 2b). This finding implies 
increased permeability induced by Ang-2 and is in line 
with a previous report suggesting that in contrast to Ang-2, 
Ang-1 increases the glycocalyx depth and reduces vascular 
permeability [31, 49]. To further elaborate the permeabil-
ity in GOF mice, we analyzed the permeability of circulat-
ing HRP tracer by EM. We observed a greater number of 
HRP-positive vesicles in Ang-2 GOF mice compared to 
WT mice (Fig. 5b; Suppl. Table 3). These data indicate that 
Ang-2 could lead to transcellular vesicular permeability 
and are in line with previous work showing increased cave-
olae-mediated transport upon pericyte loss and subsequent 
permeability in genetic mouse models [4]. Western blots 
of isolated mouse brain microvessels (MBMV) revealed a 
downregulation of VE-cadherin and claudin-5 in GOF ani-
mals, whereas caveolin-1, crucial for caveolae formation 
was upregulated (Fig. 5c). These data support the EM data 
that indicated increased numbers of vesicles and gaps in 
junctions (Figs. 4, 5b; Suppl. Fig. 2a). Glut-1 and β-catenin 
were however unaltered (Fig. 5c). However, mRNA levels 
of MECA 32, a plasmalemma vesicle-associated protein 
(PLVAP), and Mfsd2a that is associated with increased 
vesicular formation upon pericyte degeneration, were not 
altered (Suppl. Fig. 4a). Further, flow cytometry analyses 
revealed an increased number of myeloid cells in brains 
derived from Ang-2 GOF mice compared to WT mice 
(Suppl. Fig. 3a), a finding that is consistent with previous 
observations [52]. Together, these data indicate an effect of 
Ang-2 on both paracellular and transcellular permeability.  
Fig. 1  Ang-2 increases brain 
endothelial permeability 
in vitro. a MBMECs from WT 
and Ang-2 GOF brains were 
seeded on transwell inserts and 
transferred to a cellZscope® 
system to obtain continuous 
TEER values. The inset shows 
a transwell insert along with top 
and bottom electrodes typical 
of a cellZscope® device. The 
graph shows a representa-
tive experiment that indicates 
reduced TEER values in Ang-2 
GOF MBMECs compared to 
WT that is sustained up to 48 h 
post-seeding when the monolay-
ers reach confluency. b GOF 
MBMECs showed lower TEER 
than control cells at 24 and 
48 h. c WT-MBMECs treated 
with hAng-2 resulted in reduced 
TEER. d hAng-2 treatment 
resulted in increased tracer flux 
across MBMECs (b–d, n = 3)
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Astrocytes play an essential role in BBB permeabil-
ity [2]. Aquaporin-4 IHC did not show any change in the 
astrocytic endfeet coverage of GOF brain vessels (Suppl. 
Fig. 3b). However, EM analysis revealed astrocytic endfeet 
swelling (Fig. 4a) and occasional pericyte degeneration 
(Fig. 4a, c; Suppl. Table 1), also indicative of neurovascu-
lar uncoupling. These results together suggest that Ang-2 
increases BBB permeability by modulating both paracellu-
lar junctions and transcellular vesicular transport systems.
The above-mentioned findings prompted us to investi-
gate the potential role of Ang-2 in human cerebrovascular 
disease. Expression levels of Ang-2 were assessed by IHC 
in human brain autopsy specimens and by ELISA in stroke 
patients compared to healthy volunteers. While Ang-2 
expression was almost absent in normal brain tissue, the 
levels were higher in stroke grades I and II that are char-
acterized by BBB leakage (Fig. 6a, b) and returned to low 
expression levels in grade III lesions (Fig. 6a, b). Serum 
analysis from stroke patients indicated a significantly 
higher level of hAng-2 in patients with territorial stroke 
compared to healthy humans (Fig. 6c). We subsequently 
employed a mouse permanent middle cerebral artery occlu-
sion (pMCAO) model, where significantly larger infarcts 
were detected in Ang-2 GOF mice after 24 and 72 h com-
pared to WT mice (Fig. 7a), whereas at 7 days post-stroke 
differences in infarct size between WT and GOF resolved. 
Additionally, the IgG permeability in the stroke area was 
increased in GOF mice compared to WT 24 h after occlu-
sion (Fig. 7b) corroborating the permeability effects of 
Ang-2 in a stroke model.
We had previously observed increased Ang-2 levels 
in WT rodents subjected to MCAO [7] and thus sought 
to investigate the rescue of stroke size/permeability in 
WT mice by interference with Ang-2/Tie2 signaling. To 
Fig. 2  Permeability analysis of Ang-2 GOF mice in vivo. a Perme-
ability to LY and Texas Red-3 kD/TMR-dextran was higher in GOF 
brains (LY: n = 7, TXR: WT n = 12; GOF n = 16). b Evans blue dye 
permeability was not altered (n = 6). c Increased permeability of 3 
kD TMR-dextran in Ang-2 GOF mice in cortex and subcortical white 
matter (SWM) (n = 3, scale bars 10 µm)
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this end, we employed the more clinically relevant tran-
sient MCAO (tMCAO) model in WT mice and aimed a 
rescue with AKB-9785 (gift from Aerpio Therapeutics), 
a drug targeting Tie2 signaling by blocking the activity 
of the vascular endothelial protein tyrosine phosphatase 
(VE-PTP) that is associated with Tie2 and VE-cadherin 
[54]. In vitro, MBMECs/bEnd5 pre-treated with hAng-2 
followed by AKB-9785 treatment showed an increase 
in pTie2 and pAkt, but not in pVE-cadherin (Fig. 8a, 
b), associated with decreased junctional permeability 
as shown by increased TEER of MBMECs after 24 and 
48 h (Fig. 8c) as well as decreased capacitance (Ccl) val-
ues (Suppl. Fig. 4b). The permeability effect of hAng-2 
decreased in combination with AKB-9785 (Fig. 8c, d). 
Upon filipin treatment, a compound blocking the forma-
tion of caveolae, no differences in 3 kD dextran tracer 
between control, hAng-2 and hAng-2 plus AKB-9785 
could be detected anymore (Fig. 8d). These data support 
our hypothesis that hAng-2 causes permeability partly by 
transcellular vesicular permeability and that AKB-9785 is 
able to prevent this effect. In the 67 kD BSA-Alexa 647 
tracer, this effect was abolished, suggesting that Ang-2 
induced BBB permeability primarily facilitates transi-
tion of smaller molecules (Suppl. Fig. 4c). The effect of 
AKB-9785 is endothelial specific, as phosphorylation of 
Akt could neither be detected in pericytes (Fig. 8e) nor 
in astrocytes (Suppl. Fig. 4d). WT tMCAO mice treated 
with AKB-9785 displayed reduced infarcts (Fig. 9a) and 
permeability to IgG (Fig. 9c) with a post-stroke neuro-
logical improvement 72 h after occlusion (Fig. 9b). The 
AKB-9785-treated hemispheres from mice subjected to 
tMCAO showed increased pTie2/pAkt activity (Fig. 9d, 
e). This finding is indicative of a restoration of the Tie2 
signaling as pTie2 staining in AKB-9785-treated stroke 
brains appeared almost similar to pTie2 staining in nor-
mal brain vessels (unaffected hemispheres; Suppl. Fig. 5, 
compare to Fig. 9e). We next ascertained whether the 
increased permeability upon stroke in Ang-2 GOF mice 
was a direct effect of Ang-2 or secondary to stroke that 
is associated with impaired BBB. To this end, we per-
formed permeability analyses at 3 h post-stroke, a time 
point associated with minimal infarct sizes. The results 
revealed already increased extravasation of 3 kD TMR-
dextran in Ang-2 GOF mice 3 h post-stroke suggesting 
that Ang-2-mediated permeability could contribute to 
edema formation and thus facilitate larger infarct size at 
later time points (Suppl. Fig. 4e). These results are further 
supported by the therapeutic rescue achieved by adminis-
tration of AKB-9785, potentially reducing BBB leakage 
by VE-PTP-dependent activation of Tie2 signaling.
Fig. 3  Immunohistochemistry analysis of pericytes in Ang-2 GOF 
mice. a Pericytes (desmin+) were decreased in GOF mice utilizing 
10 µm cryosections for analysis (n = 8, scale bars 25 µm). b 50 µm 
vibratome sections of Ang-2 GOF and WT mice revealed decrease 
in pericyte area/vessel area [%] (n = 3, scale bars 10 µm) indicating 
decreased pericyte coverage of the vessels in GOF mice
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Discussion
Brain endothelium is the principal site of BBB regulation, 
which largely restricts the access of plasma components to 
the brain parenchyma. The BBB is disturbed in many neu-
rological disorders resulting in increased cerebrovascular 
leakage and brain edema [16, 56]. It is well established 
that Ang-2 influences permeability in peripheral vascular 
beds [11, 64]; however, its role in regulating the perme-
ability of specialized brain endothelium is still unclear and 
was thus the focus of the present study. Our results demon-
strate that endothelial cell-derived Ang-2 is able to increase 
brain endothelial permeability in vitro and in vivo and is 
associated with increased stroke size. Activating Tie2 sign-
aling by an inhibitor of VE-PTP partly reversed cerebrovas-
cular permeability and increased neurological function in a 
mouse stroke model.
In our previous work, we showed that Ang-2 GOF in 
ECs leads to a loss of pericytes in the peripheral vessels 
[53], an effect which was likewise observed in other studies 
and associated with an increase in endothelial permeability 
[64]. In conjunction with the established role of pericytes 
in regulating the permeability of BBB [4, 10, 18], we thus 
aimed to investigate whether Ang-2 also affects the permea-
bility of the BBB. To this end, we utilized electrical imped-
ance measurements to obtain continuous barrier tightness 
Fig. 4  Ultrastructural analysis of Ang-2 GOF mice. a EM revealed 
swollen astrocytic endfeet, degenerating pericytes and more vesi-
cles and gaps (arrows) between ECs in GOF. AEF astrocytic end-
feet, BL basal lamina, PC pericyte (scale bar sizes are indicated in 
the images). b The pericyte coverage analyzed from EM images is 
decreased in Ang-2 GOF mice (100 vessels were analyzed; n = 5). 
c Increased pericyte degeneration was observed in Ang-2 GOF 
mice (100 vessels analyzed; n = 5). d The gaps within EC junction 
increased in Ang-2 GOF mice (100 vessels analyzed; n = 5). e The 
number of cortical vesicles of ECs in Ang-2 GOF mice increased 
(20 vessels of similar size 4–5 µm lumen per mouse were analyzed; 
n = 3)
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indices of the primary cultured mouse brain endothe-
lial cells (MBMECs). Our results established that TEER 
of MBMECs was decreased upon recombinant Ang-2 
treatment or upon Ang-2 GOF, indicative of a barrier-open-
ing effect of Ang-2. We also observed increased capaci-
tance (Ccl) values in Ang-2 GOF MBMECs, reflective of 
Fig. 5  Detection of the glycocalyx and plasma tracers by EM anal-
ysis: a lanthanum nitrate was used to detect the glycocalyx (black 
arrows) in mouse brain vessels. Glycocalyx was decreased/disrupted 
from ~300 to ~100 nm in GOF mice. b HRP was intravenously 
injected into WT and Ang-2 GOF mice and circulated for 30 min. 
Representative images of Ang-2 GOF mice revealed HRP-vesicles 
(black arrows) with affected endothelial junctions (red arrows). 
Quantitative analysis indicated more HRP-positive vesicles in Ang-2 
GOF mice (20 vessels analyzed; n = 3; scale bar sizes are indicated 
in the images). c MBMV Western blots showed decreased VE-cad-
herin and claudin-5 in GOF, whereas caveolin-1 was upregulated 
(n = 3)
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an increase in transcellular permeability as capacitance is a 
property of the cellular membranes in storing charges (dis-
cussed in detail in [15]). However, as TEER and Ccl are 
indicative of permeability to ions, we extended the Ang-
2-mediated permeability of MBMECs to other solutes [15] 
and observed that Ang-2 increased permeability to tracers 
of different sizes.
To confirm the observed permeability effects of Ang-2 
on brain endothelium in transgenic mice in vivo, we per-
formed fluorescent tracer studies. For these experiments, 
we specifically chose to employ endothelial-specific Ang-2 
GOF mice as compared to recombinant Ang-2 treatment, as 
the former is specific to the effects arising from ECs, the 
principal site of Ang-2 expression. We initially tested the 
leakage of large dyes such as Evans blue (~70 kD) in mice 
that express transgenic Ang-2 in EC. There was no dif-
ference in Evans blue dye leakage between WT and GOF 
mice indicating that the barrier-opening effects of Ang-2 
in vivo to bigger tracers was lower than that in vitro where 
70 kD FITC-dextran permeability was increased twofold. 
However, the permeability to LY and 3 kD TXR/TMR-dex-
tran was increased in Ang-2 GOF mice in vivo. Thus, our 
results clearly demonstrate that endothelial-derived Ang-2 
regulates the size-based permeability at the healthy BBB. 
Our observations extend previous findings on permeability-
modulating functions of Ang-2 in peripheral vascular beds 
[11, 64] to the highly specialized endothelium at the BBB. 
As Ang-1 and Ang-2 have an established role as antagoniz-
ing molecules, our findings are additionally in line with 
former reports on barrier-tightening effects of Ang-1 in 
the skin of genetically engineered mice [59, 60]. The size-
based permeability in vivo most likely reflects an extremely 
tight barrier that, however, is compromised in brain EC 
monolayer cultures in vitro [20]. We hypothesize that the 
differences in Evans blue dye versus smaller sized tracers 
may be due to the size-based permeability arising from 
Fig. 6  Ang-2 expression analysis in normal brain and human stroke 
samples (grade I–III). a, b H&E/IHC staining of human stroke sam-
ples showed higher Ang-2 expression in the stroke area (n = 13). 
NAWM normal appearing white matter, NAGM normal appearing 
gray matter, i infarct, pn penumbra. c Serum ELISA from stroke 
(n = 4-lacunar, n = 15-territorial) and healthy subjects (n = 16) 
showed highest Ang-2 levels in territorial strokes
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gaps in EC junctions. It could also arise due to differences 
in diffusion time that is a function of the tracer size and 
route—paracellular versus transcellular, which is mediated 
by vesicles and potentially receptor-based transport. More-
over, the size-restricted permeability could also be a result 
of greater clearance of the Evans blue dye from circula-
tion at later time points than observed for smaller tracers. 
To address this issue in more detail, we assessed regional 
differences in permeability by immunofluorescence of 
injected tracers using anti-dye antibodies to enhance the 
signal. In two regions investigated, namely cortex and sub-
cortical white matter (SWM), we observed an increase in 3 
kD dextran extravasation in Ang-2 GOF mice, as indicated 
by extravascular dye staining and a loss of vascular stain-
ing. In contrast, the dye remained restricted to the vessels 
in the WT mice.
The molecular components of the Ang-2-mediated 
increase in endothelial permeability was elaborated by 
immunohistochemistry (IHC) and ultrastructural analy-
sis (electron microscopy) of the neurovascular unit in 
Ang-2 GOF mice and by biochemical analyses of isolated 
microvessels. It has previously been reported that astrocytic 
endfeet coverage has an essential role in barrier permeabil-
ity [30, 35], and more recently it was shown that pericytes 
are essential for maintaining low BBB permeability by pre-
venting caveolae-mediated transcytosis [4]. Our results do 
not directly parallel the former findings, because we did not 
observe changes in astrocytic endfeet coverage in Ang-2 
GOF as demonstrated by IHC with the astrocyte endfeet 
marker aquaporin-4. However, our EM analysis indicated 
neurovascular uncoupling as inferred from astrocytic end-
feet swelling as well as pericyte degeneration. Apart from 
this, an Ang-2-mediated effect on peri-vascular cells in 
brains of Ang-2 GOF mice is indicated by decreased peri-
cyte coverage, which is in line with previous finding of per-
icyte loss in peripheral vessels of the GOF mice [53]. Our 
Fig. 7  Analysis of stroke 
severity in Ang-2 GOF mice. a 
pMCAO infarcts were larger in 
GOF (24 h, WT, GOF n = 4; 
72 h, WT n = 10, GOF n = 7; 
7 days, WT, GOF n = 5). b 
IgG permeability in the infarct 
area was higher in GOF (n = 6) 
compared to WT (n = 4)
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EM analysis further indicated increased flask-shaped plas-
malemmal vesicles in Ang-2 transgenic mice reminiscent 
of caveolae, a subset of the lipid rafts that are responsible 
for higher endothelial permeability of peripheral vessels 
[13]. These results are supported by findings using HRP, 
a plasma tracer that was injected intravenously followed 
by EM. Our results clearly evidenced higher numbers of 
HRP-positive vesicles in Ang-2 GOF when normalized to 
the total number of vesicles, indicative for transcytosis of 
blood-borne tracers via vesicles in Ang-2 GOF mice. These 
data are in line with previous work showing an increase in 
caveolae-mediated transport upon pericyte loss and subse-
quently enhanced permeability [4]. The EM analysis also 
revealed the decreased length of the inter-endothelial junc-
tions with frequent gaps indicative of increase in paracellu-
lar permeability mediated by Ang-2. To gain further insight 
on brain vessel morphology at the BBB, we investigated 
the luminal glycocalyx size in Ang-2 GOF and WT mice, 
as it had previously been established that the glycocalyx 
influences vascular permeability via its binding to plasma 
proteins [55]. By means of lanthanum nitrate staining, we 
demonstrated that the glycocalyx in GOF mice was consid-
erably decreased and disrupted in all vessels. Furthermore, 
we observed particles of lanthanum nitrate on the ablumi-
nal side deposited in the basement membrane, which were 
occasionally found in intracellular vesicles suggesting tran-
scytosis of glycocalyx fragments. Although it is currently 
unclear how Ang-2 mediates the shedding of glycocalyx, 
our ultrastructural analyses clearly substantiated the dis-
rupted barrier functions in Ang-2 GOF mice that ultimately 
led to increased permeability.
We performed further biochemical analyses on mouse 
brain microvessels to assess the involvement of permeabil-
ity-related molecules, both junctional and those involved 
in transcellular transport. The analyses revealed the down-
regulation of VE-cadherin, a crucial adherens junction mol-
ecule, as well as claudin-5, a tight junction molecule. The 
obtained results fully support our observations at the ultra-
structural level that revealed gaps in endothelial junctions. 
Furthermore, caveolin-1, a scaffolding protein crucial for 
caveolae formation, was upregulated, once again reassuring 
EM data that showed increased caveolae-like vesicles in the 
Ang-2 GOF mice. We however did not observe any change 
in Glut-1, a transendothelial facilitative glucose trans-
porter, suggesting that specific modulations of junctional 
and vesicular proteins caused by Ang-2 result in the per-
meability increase of the brain microvasculature. Our study 
consequently demonstrates that Ang-2 increases both the 
paracellular and the transcellular permeability at the BBB.
These findings may have clinically relevant implica-
tions for neurological disorders that are associated with 
BBB disturbance and cerebral edema, including hem-
orrhagic and ischemic stroke, traumatic brain injury, 
epilepsy, neurodegenerative disease, high-altitude disease 
as well as primary and metastatic brain neoplasia [16, 56]. 
Of note, Ang-2 has been shown to be upregulated in the 
activated endothelium in stroke and glioblastoma models 
in rodents as well as in glioblastoma patients [7, 32, 52, 
57], suggesting that therapeutic interference with Ang-2/
Tie2 signaling may be particularly useful to prevent BBB 
disruption in those disorders. The successful targeting of 
Ang-2-mediated BBB breakdown has previously been 
emphasized in preclinical models of orthotopic glioma 
and breast cancer metastasis to the brain [6, 52]. In our 
study, we specifically aimed to interfere with the BBB 
breakdown in mouse models of cerebral ischemia. Stroke 
is a leading cause of death and the most common cerebro-
vascular disorder, characterized by an initial breakdown of 
the BBB with increased edema into the surrounding brain 
parenchyma [8, 50]. We have previously demonstrated 
increased endothelial-derived Ang-2 levels in a rodent 
experimental ischemic stroke model [7] and in the present 
study therefore investigated the potential role of Ang-2 
in stroke patients. Indeed, similar to our findings in the 
rodent stroke models, autopsy cases revealed increased 
Ang-2 expression levels in stroke grade I and II samples. 
As expected, in stroke grade III that is characterized by 
cysts, glial scar tissue and a largely recovered BBB func-
tion, Ang-2 went back to normal levels. Interestingly, 
Ang-2 serum levels were significantly higher in patients 
with large, territorial infarcts compared to serum levels in 
healthy volunteers. However, patients with smaller, lacu-
nar infarcts had levels more similar to healthy volunteers. 
These findings are in line with previous reports identify-
ing Ang-2 as a crucial risk factor in a variety of cardiovas-
cular diseases, including myocardial infarction, and thus 
suggest that Ang-2 serum levels might in addition serve 
as useful biomarkers to assess endothelial dysfunction in 
stroke patients [33, 38].
To more directly assess the impact of Ang-2 in stroke 
at the molecular level, a permanent MCAO stroke model 
was employed in Ang-2 GOF mice. Our data further sup-
port the involvement of Ang-2 in stroke pathophysiology, 
since we observed larger infarcts and increased permeabil-
ity in GOF mice at 24 h that were also present at 72 h post-
stroke albeit to a lower extent, potentially due to a greater 
BBB recovery at the later time point [48]. At 7 days post-
stroke when BBB function is significantly recovered, no 
differences were observed in stroke size between the WT 
and GOF mice. To elaborate the permeability effects of 
Ang-2 in settings of cerebrovascular disease, we performed 
tracer experiments with a small molecular weight tracer 
(3 kD dextran) in the GOF mouse model. While dextran 
was mostly restricted to vessels in the WT mice 3 h post-
stroke, extravascular dye was detected in the GOF mice. 
Our results strongly correlate with the clinical findings and 
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implicate Ang-2 as an important mediator of permeability/
BBB breakdown upon cerebral ischemia in mice.
Based on these findings, we explored the therapeutic 
rescue of experimental stroke in mice using an inhibitor 
of the vascular endothelial protein tyrosine phosphatase 
(VE-PTP), a pivotal negative regulator of Tie2 signaling 
[54]. Therapeutic targeting of VE-PTP in retinal/choroidal 
vascular diseases was emphasized by Shen et al. [54], as 
interference with VE-PTP signaling via AKB-9778 stabi-
lized the ocular vasculature, even in the presence of high 
amounts of endogenous Ang-2. Pharmacological VE-PTP 
inhibition using the same inhibitor led to tumor vessel 
normalization through Tie2 activation and delayed tumor 
growth as well as metastatic progression [29]. VE-PTP also 
associates with VE-cadherin, whereby it supports the adhe-
sive activity of VE-cadherin and the integrity of endothe-
lial cell connections [12, 42]. Consistent with the role of 
VE-PTP as a negative regulator of Tie2 activation, our 
results clearly demonstrate that both pTie2 and pAkt were 
increased, whereas VE-cadherin was decreased upon AKB-
9785 treatment [27]. Our findings thus imply that AKB-
9785 activates Tie2 signaling at the BBB, independent of 
VE-cadherin phosphorylation. Importantly, this finding is 
in line with recent observations in a lung leukocyte trans-
migration model [27]. The authors of this study elegantly 
demonstrated that interference with VE-PTP stabilizes 
endothelial junctions in non-brain endothelial cells via Tie2 
in the absence of VE-cadherin [27]. Our results demon-
strate that AKB-9785 was able to rescue Ang-2-mediated 
permeability effects in vitro supporting its BBB tighten-
ing effects. Furthermore, Ang-2-mediated increase in per-
meability was not present after treatment with filipin, a 
compound that is known to disrupt caveolae, indicating 
that Ang-2 affects permeability by paracellular and vesicu-
lar pathways. To explore the potential therapeutic effects, 
AKB-9785 was evaluated in a transient MCAO model that 
is more reflective of human stroke pathophysiology than the 
previously employed permanent MCAO model. The effects 
of the inhibitor were assessed 24 h post-MCAO, a time 
point with pronounced BBB damage [48]. We observed a 
diminished stroke size compared to the control group with 
a concomitant neurological improvement after 72 h. This 
was accompanied by a decrease in permeability in the 
stroke area of treated animals. Activation of Tie2 signaling 
in vivo was supported by IHC showing the restoration of 
pTie2 staining in AKB-9785-treated MCAO brains. This 
finding is further supported by Western blot analysis show-
ing Akt activation in AKB-9785-treated stroke samples, as 
well as primary brain EC. AKB-9778, a compound closely 
related to AKB-9785, was previously shown to have similar 
anti-permeability effects via Tie2 pathway and independ-
ent of the adhesive activity on VE-cadherin [27, 29, 54]. 
As such, the VE-PTP inhibitor AKB-9785 restores pTie2 
to levels that ensure proper vascular function, consistent 
with the finding that pTie2 is constitutively expressed in the 
normal adult rodent brain [62]. Further, the current analy-
sis indicates that the specific effects of the VE-PTP inhibi-
tor AKB-9785 in improving stroke outcome are mediated 
solely by restoring Tie2 signaling and are independent of 
VE-cadherin phosphorylation.
The permeability of the BBB was also shown to be reg-
ulated by Wnt/β-catenin signaling effecting both the brain 
vascular development and maintenance of barrier proper-
ties [37]. Sonic hedgehog signaling has also been demon-
strated to contribute to barrier maturation [3] and, more 
recently, the retinoic acid signaling has been shown to be 
a novel regulator of BBB function [41]. It is, however, not 
known if the above pathways are interacting in controlling 
BBB function. In this regard, it was recently demonstrated 
that shear stress increased Ang-2 expression via activa-
tion of the canonical Wnt pathway in aortic endothelial 
cells, an effect that was reversed with Wnt inhibition [36]. 
Similar findings were also observed in vascular repair in 
zebrafish. However, the authors did not assess the role of 
Ang-2 in inhibiting Ang-1-mediated Tie2 signaling which 
has an established role in maintaining vessel integrity 
[60]. Such a role for Ang-2 in vascular repair is supported 
by previous studies showing vascular regression in the 
absence of VEGF [32] and our work showing blood–brain 
barrier-stabilizing effects of canonical Wnt pathway [37]. 
The role of sonic hedgehog (shh) pathway in regulating 
angiopoietins has been reported in vitro in NIH 3T3 cells 
that do not express shh protein [34]. It was demonstrated 
using recombinant shh that resulted in the activation of 
target gene Gli1 and also led to the upregulation of Ang-1 
mRNA and downregulation of Ang-2 mRNA. This effect 
was reversed in the loss of function experiments using 
cyclopamine, a specific inhibitor of the shh signaling path-
way. The above role of shh in regulating Ang-1/Ang-2 is 
well supported by the established vessel maturation and 
barrier maintenance roles of the shh pathway [3]. Our 
finding that Ang-2 signaling plays a role in brain vascu-
lar permeability opens up the emerging question whether 
angiopoetin/Tie-2 signaling acts independently or in con-
junction with other pathways.
Fig. 8  Effects of AKB-9785 treatment in vitro. a MBMECs pre-
treated with hAng-2 increased Tie2/Akt activation upon AKB-9785 
treatment (n = 3). b bEnd5 Western blots revealed Tie2/Akt activa-
tion, but a decrease (non-significant) in pVE-cadherin by AKB-9785 
(n = 3). c MBMECs pre-treated with recombinant hAng-2 [500 ng/
ml] followed by AKB-9785 [1 µM] treatment revealed increased 
TEER values. d The in vitro permeability tracer experiment with a 3 
kD Texas Red-dextran showed a decrease in permeability with AKB-
9785 + hAng-2 compared to hAng-2 treatment alone. This difference 
was not detected in the presence of filipin. e The phosphorylation of 
Akt in Western Blot analysis could only be identified in MBMECs, 
but not pericytes (n = 3)
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Fig. 9  Therapeutic targeting of Tie2 signaling using AKB-9785 
in WT mice subjected to tMCAO. a TTC staining after tMCAO (3/
group) showed significantly smaller infarcts 24 h post-stroke upon 
AKB-9785 treatment (n = 13). b An mNSS behavioral analysis of 
control and mice treated with AKB-9785 (30 mg/kg) showed a neuro-
logical improvement in treated mice 72 h after stroke incidence (24 h: 
control n = 8, AKB-9785 n = 9; 72 h: control n = 7, AKB-9785 
n = 9). The neurological deficit scoring is described in “Materials 
and methods” and is composed of testing flexion, gait, coordination 
and sensory functions. The total scoring included all four behavio-
ral tests (2-tailed unpaired non-parametric Mann–Whitney test). c 
IgG staining showed significantly lower permeability in AKB-9785 
treated mice (n = 6). d Western blots of stroke hemisphere showed 
increased Akt activation in AKB-9785-treated mice (n = 7). e Tie2/
pTie2 staining of the stroke hemisphere revealed significantly higher 
pTie2, but not total Tie2 levels in AKB-9785-treated animals (n = 5)
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In summary, we demonstrated that Ang-2 is a critical 
mediator of cerebrovascular permeability in vivo as evi-
denced in Ang-2 GOF mice and in models of experimen-
tal stroke. We further showed larger infarcts in Ang-2 GOF 
mice that corroborate data obtained in humans where the 
stroke grade and size correlated with Ang-2 expression 
levels. The Ang-2-mediated effect in stroke models was 
rescued by targeting Tie2/Akt signaling in a VE-PTP-
dependent manner. We conclude that Ang-2 is a predomi-
nant regulator of BBB permeability and that targeting the 
angiopoietin/Tie2 signaling could lead to clinically rel-
evant therapeutics for tightening the BBB in neurological 
disorders as shown here for ischemic stroke by employ-
ing a novel VE-PTP inhibitor. Vice versa, modulating Tie2 
signaling could potentially be used for opening the BBB to 
facilitate drug delivery to the CNS.
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